Click on a filter below to refine your search. Remove a filter to broaden your search.
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.
The findings were seen across cardiometabolic common mental disorder and mortality outcomes.
Proportionately lower log odds were seen for heart disease, heart attack, stroke and composite outcome for days of use between zero and 30 a month.